triazoles has been researched along with AIDS Dementia Complex in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agsalda, M; Chew, GM; Chow, DC; Hanks, N; Ho, E; Kallianpur, KJ; Nakamoto, B; Ndhlovu, LC; Paul, R; Shikuma, CM; Shiramizu, BT; Umaki, T; Zhang, G | 1 |
| Brew, BJ; Chaganti, J; Cysique, LA; Gates, TM; Moffat, KJ; Siefried, KJ | 1 |
1 trial(s) available for triazoles and AIDS Dementia Complex
| Article | Year |
|---|---|
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
Topics: Aged; AIDS Dementia Complex; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2016 |
1 other study(ies) available for triazoles and AIDS Dementia Complex
| Article | Year |
|---|---|
Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associa
Topics: Acquired Immunodeficiency Syndrome; Aged; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Disease Management; Female; Gene Expression; GPI-Linked Proteins; HIV-1; Humans; Leukocyte Count; Male; Maraviroc; Middle Aged; Monocytes; Neuropsychological Tests; Receptors, CCR5; Receptors, IgG; Triazoles; Viral Load | 2014 |